Fetal Tachyarrhythmia - Part II: Treatment

Oudijk, Martijn A and Visser, Gerard HA and Meijboom, Erik J (2004) Fetal Tachyarrhythmia - Part II: Treatment. [Journal (Paginated)]

Full text available as:



The decision to initiate pharmacological intervention in case of fetal tachycardia depends on several factors and must be weighed against possible maternal and/or fetal adverse effects inherent to the use of antiarrhythmics. First, the seriousness of the fetal condition must be recognized. Many studies have shown that in case of fetal tachycardia, there is a significant predisposition to congestive heart failure and subsequent development of fetal hydrops and even sudden cardiac death1,2,3 Secondly, predictors of congestive heart failure have been suggested in several studies, such as the percentage of time that the tachycardia is present, the gestational age at which the tachycardia occurs4, the ventricular rate5 and the site of origin of the tachycardia6. However, the sensitivity of these predictors is low and they are therefore clinically not very useful. In addition, hemodynamic compromise may occur in less than 24 - 48 hours as has been shown in the fetal lamb7 and in tachycardic fetuses8,9. On the other hand, spontaneous resolution of the tachycardia has also been described10. Thirdly, transplacental management of fetuses with tricuspid regurgitation11, congestive heart failure or fetal hydrops is difficult12,13, probably as a result of limited transplacental transfer of the antiarrhythmic drug14,15. In case of fetal hydrops, conversion rates are decreased and time to conversion is increased13. Treatment of sustained fetal tachycardia is therefore to be preferred above expectant management, although some centers oppose this regimen and suggest that in cases with (intermittent) fetal SVT not complicated by congestive heart failure or fetal hydrops, conservative management and close surveillance might be a reasonable alternative16,17,18.

Item Type:Journal (Paginated)
Keywords:Fetal Tachyarrhythmia
Subjects:JOURNALS > Indian Pacing and Electrophysiology Journal
ID Code:4183
Deposited By:Indian Pacing and Electrophysiology, Journal
Deposited On:14 Apr 2005
Last Modified:11 Mar 2011 08:55

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Strasburger JF. Fetal arrhythmias. Prog Pediatr Cardiol 2000;11(1):1-17

2. Allan LD, Anderson RH, Sullivan ID, et al. Evaluation of fetal arrhythmias by echocardiography. Br Heart J 1983;50:240-24

3. Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound 1985;13:265-273

4. Naheed ZJ, Strasburger JF, Deal BJ, Benson DW, Gidding SS. Fetal tachycardia: mechanisms and predictors of hydrops fetalis. J Am Coll Cardiol 1996;27:1736-40

5. Gunteroth WG, Cyr DR, Shields LE, et al. Rate based management of fetal supraventricular tachycardia. J Ultrasound Med 1996;15:453-8

6. Kleinman CS, Nehgme R, Copel JA, et al. Fetal cardiac arrhythmias: diagnosis and therapy. In: Creasy RK, Resnik R, editors. Matern-fetal medicine. Philadelphia (PA): Saunders, 1998:301-318

7. Gest AL, Hansen TN, Moise AA, Hartley CJ. Atrial tachycardia causes hydrops in fetal lambs. Am J Physiol 1990;258:H1159-63

8. Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound 1985;13:265-273

9. Allan LD. Cardiac ultrasound of the fetus. Arch Dis Childhood 1984;59:603-604

10. Wladimiroff JW, Stewart PA. Treatment of fetal cardiac arrhythmias. Br J Hosp Med 1985: 134-140

11. Jouannic JM, LeBidois J, Fermont L, et al. Prenatal ultrasound may predict fetal response to therapy in non-hydropic fetuses with supraventricular tachycardia. Fetal Diagn Ther 2002;17:120-123

12. Hansmann M, Gembruch U, Bald R, et al. Fetal tachyarrhythmias: transplacental and direct treatment of the fetus. A report of 60 cases. Ultrasound Obstet Gynecol 1991;1:162-170

13. Parilla BV, Strasburger JF, Socol ML. Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. Am J Perinatol 1996;13:483-486

14. Kofinas AD, Simon NV, Sagel H, et al. Treatment of fetal supraventricular tachycardia with flecainide acetate after digoxin failure. Am J Obstet Gynecol 1991;165: 630-1

15. Younis JS, Granat M. Insufficient transplacental digoxin transfer in severe hydrops fetalis. Am J Obstet Gynecol 1987;157:1268-1269

16. Simpson LL, Marx GR, D`Alton ME. Supraventricular tachycardia in the fetus: conservative management in the absence of hemodynamic compromise. J Ultrasound Med 1997;16:459-464

17. Gunteroth WG, Cyr DR, Shields LE, et al. Rate-based management of fetal supraventricular tachycardia. J Ultrasound Med 1996;15:453-458

18. Cuneo BF, Strasburger JF. Management strategy for fetal tachycardia. Obstet Gynecol 2000;96:575-81

19. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med 1985;312:82-90

20. Berkowitz GS, Papiernik E. Epidemiology of preterm birth. Epidemiol Rev 1993;15:414-43

21. Lydon-Rochelle M, Holt VL, Easterling, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. N Engl J Med 2001;345(1):3-8

22. Gielchinsky Y, Rojansky N, Fasouliotis SJ, Ezra Y. Placenta accreta—summary of 10 years: a survey of 310 cases. Placenta 2002;23(2-3):210-4

23. Webb JC, Gilson G, Gordon L. Late second stage rupture of the uterus and bladder with vaginal birth after cesarean section: a case report and review of the literature. Matern Fetal Med 2000;9(6):362-5

24. Hallak M, Neerhof MG, Perry R, Nazir M, Huhta JC. Fetal supraventricular tachycardia and hydrops fetalis: combined intensive, direct, and transplacental therapy. Obstet Gynecol. 1991 Sep;78(3 Pt 2):523-5

25. Kohl T, Tercanli S, Kececioglu D, et al. Direct fetal administration of adenosine for the termination of incessant supraventricular tachycardia. Obstet Gynecol 1995;85:873-874

26. Maxwell DJ, Crawford DC, Curry PVM, et al. Obstetric importance, diagnosis, and management of fetal tachycardias. Br Med J 1988;297:107-110

27. Rogers MC, Willerson JT, Goldblatt A, et al. Serum digoxin concentrations in the human fetus, neonate and infant. N Engl J Med 1972;16:1010-3

28. Chan V, Tse TF, Wong V. Transfer of digoxin across the placenta and into breast milk. Br J Obstet Gynaecol 1978;85:605-9

29. Van Engelen AD, Weijtens O, Brenner JI, et al. Management, outcome and follow-up of fetal tachycardia. J Am Coll Cardiol 1994;24:1371-5

30. Frohn-Mulder IM, Stewart PA, Witsenburg M, et al. The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. Pren Diagn 1995;15:1297-1302

31. Simpson JM, Sharland GK. Fetal tachycardias: management and outcome of 127 consecutive cases. Heart 1998;79:576-581

32. Jaeggi E, Fouron JC, Drblik SP. Fetal atrial flutter: diagnosis, clinical features, treatment, and outcome. J Pediatr 1998;132:335-339

33. Krapp M, Kohl T, Simpson JM, Sharland GK, Katalinic A, Gembruch U. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart. 2003 Aug;89(8):913-7.

34. Oudijk MA, Ruskamp JM, Ambachtsheer EB, et al. Drug treatment of fetal tachycardias. Pediatr Drugs 2002;4(1):49-63

35. Azancot-Benisty A, Jacqz-Aigrain, Guirgis NM, et al. Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias. J Pediatr 1992;121:608-13

36. Wagner X, Jouglard J, Moulin M, et al. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J 1990;119:700-702

37. Bourget P, Pons JC, Delouis C, et al. Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the third trimester of pregnancy. Ann Pharmacother 1994;28:1031-4

38. Barjot P, Hamel P, Calmelet, et al. Flecainide against fetal supraventricular tachycardia complicated by hydrops fetalis. Acta Obstet Gynecol Scand 1998;77:353-354

39. Allan LD, Chita SK, Sharland GK, Maxwell D, Priestly K. Flecainide in the treatment of fetal tachycardias. Br Heart J 1991;65:46-8

40. Ebenroth ES, Cordes TM, Darragh RK. Second-line treatment of fetal supraventricular tachycardia using flecainide acetate. Pediatr Cardiol 2001;22:483-487

41. Krapp M, Baschat AA, Gembruch U, Geipel A, Germer U. Flecainide in the intrauterine treatment of fetal supraventricular tachycardia. Ultrasound Obstet Gynecol 2002;19:158-164

42. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo, the cardiac arrhythmia suppression trial. N Engl J Med 1991;324: 781-8

43. Gembruch U, Manz M, Bald R, et al. Repeated intravascular treatment with amiodarone in a fetus with refractory supraventricular tachycardia and hydrops fetalis. Am Heart J 1989;118:1335-1338

44. Mangione R, Guyon F, Vergnaud A, et al. Successful treatment of refractory supraventricular tachycardia by repeat intravascular injection of amiodarone with long term follow-up. Prenat Diagn 2000;20:449-452

45. Hijazi ZM, Rosenfeld LE, Copel JA, et al. Amiodarone therapy of intractable atrial flutter in a premature hydropic neonate. Pediatr Cardiol 1992;13:227-229

46. Personal communication with Strasburger JF.

47. Strasburger JF, Cuneo BF, Michon MM, Gotteiner NL, Deal BJ, McGregor SN, Oudijk

MA, Meijboom EJ, Feinkind L, Hussey M, Parilla BV. Amiodarone therapy for drug-refractory fetal tachycardia. Circulation. 2004 Jan 27;109(3):375-9.

48. Oudijk MA, Ruskamp JM, Ververs FF, Ambachtsheer EB, Stoutenbeek P, Visser GH, Meijboom EJ. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol. 2003 Aug 20;42(4):765-70.

49. Oudijk MA. Fetal tachycardia, diagnosis and treatment and the fetal QT interval in hypoxia. Thesis Utrecht 2003. ISBN 90-393-3301-7.

50. Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek P, Visser GH, Meijboom EJ. Sotalol in the treatment of fetal dysrhythmias. Circulation. 2000 Jun 13;101(23):2721-6.


Repository Staff Only: item control page